Predict your next investment

Ultivue company logo
HEALTHCARE | Biotechnology
ultivue.com

See what CB Insights has to offer

Founded Year

2015

Stage

Series D | Alive

Total Raised

$97.15M

Last Raised

$50M | 3 mos ago

About Ultivue

Ultivue develops reagent-driven solutions for high-definition biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue's proprietary reagents, instruments, and bioinformatics tools will enable researchers and clinicians to realize the promise of personalized medicine through better matching of patients to therapeutic options.

Ultivue Headquarter Location

763D Concord Ave.

Cambridge, Massachusetts, 02138,

United States

617-945-2662

Latest Ultivue News

Ultivue Announces $50M Financing Round

Apr 28, 2021

Ultivue Announces $50M Financing Round April 27, 2021 10:07 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE) –Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC. This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows. Anna Yaeger, President and Portfolio Manager commented, “Ally Bridge Group is excited to be long term partners with Ultivue. We believe the company’s differentiated kit-based approach to multiplex immunofluorescence is well positioned to capitalize on the spatial biology revolution and creates maximum flexibility to support academic, biopharma, and CRO customers.” “What Ultivue has is remarkably capable. They provide fast, accurate, previously unattainable multiplexed protein marker information at high resolution and on existing hardware. It is going to be exciting to see a well-resourced, well led Ultivue offer great capabilities to the biotech and pharma oncology community,” said Keith Crandell, Co-founder & Managing Director from ARCH Ventures. “Ultivue is driving to make immunotherapy a reality for every patient that needs it with leading technology that enables advanced exploration and interrogation of tissue samples for precision medicine research. We’re proud to continue supporting the Ultivue team,” said Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures. “We’re excited to welcome our newest investors, and greatly appreciate the support from our existing investment partners,” says Jacques Corriveau, President and CEO of Ultivue. “This funding will allow us to expand our commercial efforts while also increasing the scope of our research and development in order to remain at the forefront of innovation and provide biological insights for our customers as they work to address the challenge of therapeutic response rates in patients using immunotherapy.” About Ultivue: Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Source: https://www.businesswire.com/news/home/20210427005387/en/

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ultivue

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ultivue is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ultivue Patents

Ultivue has filed 14 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Microscopy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/30/2018

7/13/2021

Molecular biology, DNA, Biotechnology, Genetics, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/30/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/13/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Transcription factors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Ultivue Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ultivue Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.